Recombinant antibodies for the selective targeting of tumor neovasculature.
Angiogenesis, the sprouting of new blood vessels from preexisting ones, is a characteristic feature of many aggressive solid tumors. Advances in the identification of markers of angiogenesis and new methodologies for the production of human recombinant antibodies are making it possible to deliver bioactive molecules to the tumor neovasculature in a selective fashion. This review illustrates how recombinant antibody derivatives may open new avenues for the imaging and therapy of angiogenesis-related diseases, such as cancer, blinding ocular disorders and rheumatoid arthritis.
Viti
Francesca
F
Swiss Federal Institute of Technology Zurich, Institute of Pharmaceutical Sciences, Winterthurerstrasse 190, CH-8057, Zurich, Switzerland.
Giovannoni
Leonardo
L
Neri
Dario
D
D000818:Animals; D000906:Antibodies / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D006801:Humans; D009369:Neoplasms / Q000098:blood supply / Q000473:pathology / Q000628:therapy*; D009389:Neovascularization, Pathologic / Q000473:pathology / Q000628:therapy*; D011994:Recombinant Proteins / Q000627:therapeutic use; D012039:Regional Blood Flow / Q000187:drug effects
D000906:Antibodies; D000911:Antibodies, Monoclonal; D011994:Recombinant Proteins